Sort
130,381 grants matching “hiv”
p53, Aging, and Cancer
$793,011Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia
$793,000Dolores Albarracin · University Of Illinois At Urbana-Champaign · DP1 · FY2020 · DA
Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia
$793,000Dolores Albarracin · University Of Illinois At Urbana-Champaign · DP1 · FY2019 · DA
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120
$792,991Abraham Pinter · Rbhs-New Jersey Medical School · R01 · FY2015 · AI
Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria
$792,986Lifang Hou · Northwestern University At Chicago · U54 · FY2020 · CA
Microbiome-driven immune changes and growth stunting in HIV-exposed uninfected children
$792,925Lisa M Bebell · Massachusetts General Hospital · R01 · FY2024 · HD
Microbiome-driven immune changes and growth stunting in HIV-exposed uninfected children
$792,899Lisa M Bebell · Massachusetts General Hospital · R01 · FY2025 · HD
A Rapid HIV RNA Detection without Sample Preparation
$792,894Hyundae Cho · Crosslife Technologies, Inc. · R33 · FY2023 · HD
Quality of Life and Aging with HIV in Rural Uganda
$792,877Mark J Siedner · Massachusetts General Hospital · R01 · FY2019 · AG
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles
$792,844Robert Turner Schooley · University Of California, San Diego · R01 · FY2018 · AI
Adolescent-tailored HIV treatment and prevention strategies in South Africa: projecting clinical benefits and value
$792,840Anne Neilan · Massachusetts General Hospital · R01 · FY2023 · HD
Natural killer cell regulation of the germinal center HIV neutralizing antibody response
$792,838Todd Christopher Bradley · Children'S Mercy Hosp (Kansas City, Mo) · R01 · FY2023 · AI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120
$792,805Asim K Debnath · New York Blood Center · R01 · FY2020 · AI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120
$792,805Asim K Debnath · New York Blood Center · R01 · FY2021 · AI
SV40-BASED COMBINATION GENETIC THERAPIES FOR HIV/SIV
$792,796Thomas Jefferson University · P01 · FY2002 · AI
Structure-function studies of the membrane-interacting domains of HIV-1 Env spike
$792,780Bing Chen · Boston Children'S Hospital · R01 · FY2020 · AI
Immune Activation and AIDS Pathogenesis in SIV-Infected Non-Human Primates
$792,774Guido Silvestri · Case Western Reserve University · P01 · FY2011 · AI
NATIONAL STUDY OF SYRINGE EXCHANGE PROGRAMS
$792,767Beth Israel Medical Ctr (New York) · R01 · FY2001 · DA
Dissecting virus neutralizing determinants to guide HCV vaccine development
$792,744Mansun Law · Scripps Research Institute, The · R56 · FY2013 · AI
The Impact of Aging and HIV Infection on Immunologic and Transcriptomic Signatures of Influenza Vaccine Response
$792,724Albert C Shaw · Yale University · R01 · FY2020 · AG
NK/DC Cross-Talk and Antiviral Response
$792,714Luis J. Montaner · Wistar Institute · R01 · FY2010 · AI
Safe Pregnancy by Infectious Disease Control in Kinshasa
$792,697University Of North Carolina Chapel Hill · U01 · FY2004 · HD
ADOLESCENT TRAJECTORIES FOR HOMELESSNESS &RISK FOR HIV
$792,640University Of California Los Angeles · R01 · FY2003 · MH
Adjuvants for Skin Immunization: Discovery and Mechanisms
$792,636Ioanna Skountzou · Emory University · R01 · FY2015 · AI
Prevalence & Pathogenesis of Pulmonary Disease in a Large Multicenter HIV Cohort
$792,629Alison Morris · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · HL